TENX

SEC Filing Summary: Synthetic Blood International, Inc. (10-K)

Business Context and Reporting Period

Company: Synthetic Blood International, Inc. (Note: Request metadata listed "Tenax Therapeutics," but the filing text identifies the registrant as Synthetic Blood International, Inc.)
Reporting Period: Fiscal year ended April 30, 2005.
Business Stage: Development stage enterprise with no commercial revenues. The company focuses on developing Oxycyte, a perfluorocarbon-based synthetic blood substitute. Development of two other products, Fluorovent (lung treatment) and an implanted glucose biosensor, is currently on hold pending additional financing.

Key Financial Metrics

Note: The company has no long-term debt listed on the balance sheet as of April 30, 2005. Current liabilities consist of accounts payable and accrued expenses.

Material Changes vs. Prior Period

• Net Loss Increase: Net loss increased by approximately $423,000 (19%) compared to fiscal 2004, driven primarily by higher General and Administrative (G&A) expenses.
• G&A Expenses: Increased by $406,705 (41%) to $1.41 million. This was largely due to a $311,000 expense related to stock warrants granted for delayed stock registration and an $80,000 increase in consulting fees for investor relations.
• R&D Expenses: Remained relatively flat, increasing slightly by $10,702 to $1.28 million, as the company shifted focus entirely to Oxycyte Phase II trials while halting other product development.
• Liquidity: Cash balances nearly doubled from $302,310 to $588,763, funded by net cash provided by financing activities of $2.39 million (sale of common stock).

Outlook, Risks, and Management Commentary

• Clinical Progress: Phase I trials for Oxycyte were completed in December 2003 with results meeting safety expectations. Phase II trials began in Q4 2004 and are expected to continue through 2006. Phase III trials may commence in 2007 if Phase II is successful.
• Going Concern: The independent auditors (Haskell & White LLP) have issued an opinion with an explanatory paragraph raising "substantial doubt" about the company's ability to continue as a going concern due to the accumulated deficit and reliance on external financing.
• Capital Needs: The company requires substantial additional funding to complete clinical trials, secure FDA approval, and establish commercial manufacturing. Management is actively pursuing private financing and strategic alliances.
• Subsequent Financing: On July 13, 2005 (post-fiscal year), the company closed a financing transaction issuing unsecured convertible debentures with a principal of approximately $1.85 million, netting approximately $1.15 million in proceeds.
• Risks: Key risks include failure of clinical trials, inability to obtain FDA approval, lack of market acceptance, and the potential obsolescence of technology if competitors succeed first.

Investor Verification Checklist

• Capital Runway: Verify if the July 2005 financing ($1.15M net) is sufficient to fund operations through the completion of Phase II trials (expected 2006) or if further dilution is imminent.
• Phase II Trial Status: Confirm the enrollment status and preliminary safety data of the ongoing Phase II trials for Oxycyte in hip surgery patients.
• Dilution Impact: Assess the impact of the 57.4 million shares reserved for conversion/exercise of debentures, options, and warrants on existing shareholder equity.
• Related Party Transactions: Review the $125,400 paid to PrimaPharm (contract manufacturer) where an officer of Synthetic Blood is a director and minority shareholder.
• Regulatory Milestones: Monitor FDA communications regarding the Phase II protocol and any potential delays in the review process.